Altria Releases Financial Report for 2024 and Q4, Net Revenue down 1.9% YoY, NJOY Performs Well

Feb.08.2025
Altria Releases Financial Report for 2024 and Q4, Net Revenue down 1.9% YoY, NJOY Performs Well
Altria releases 2024 financial report, net revenue down 1.9% YoY, NJOY brand excels in e-cigarette market.

Recently, Altria released its financial report for the fourth quarter of 2024. The company reported a full-year net income of $24.018 billion, a decrease of 1.9% compared to the previous year. After deducting excise taxes, the revenue was $20.444 billion, a slight decrease of 0.3%. The fourth quarter net income was $5.974 billion, with revenue after deducting excise taxes at $5.106 billion, a 1.6% increase compared to the same period last year.

Altria Releases Financial Report for 2024 and Q4, Net Revenue down 1.9% YoY, NJOY Performs Well
Financial report data | Image source: Altria

 

Altria's subsidiary NJOY brand has shown strong performance, with e-cigarette pod shipments totaling 12.8 million units in the fourth quarter, a 15.3% increase from the previous year. Device shipments totaled 1.1 million units, a 22.2% increase from the previous year. For the full year of 2024, pod shipments are projected to reach 46.6 million units, while device shipments are expected to reach 5 million units.

 

In response to the JUUL lawsuit, the United States International Trade Commission (ITC) has ruled in favor of JUUL's patent claims. This decision could potentially lead to a ban on the import and sale of NJOY's main product, ACE, after March 2025. Altria has stated that they are currently working on developing alternative solutions to mitigate potential risks.

 

The nicotine pouch brand "on!" as a new type of tobacco product, continues to grow its market share, with a 40.2% year-on-year increase in shipments.

 

On the other hand, Altria's traditional tobacco business continues to be under pressure, with shipments of combustible tobacco products declining by 10.2% for the year, primarily due to the proliferation of illegal e-cigarettes and pressure on consumer disposable income. The main cigarette brand Marlboro's market share slightly decreased to 41.7%, but it still maintains a leading position of 59.3% in the premium cigarette market.

 

Furthermore, Altria announced progress on its 2028 goals, with new tobacco revenue reaching $2.8 billion in 2024, a 7.7% increase from the 2022 baseline. However, there is still a gap to reach the $5 billion goal by 2028. Altria acknowledged that illegal e-cigarette activities were hindering goal attainment and is currently reassessing its strategy.

 

Altria's CEO, Billy Gifford, stated:

 

In 2024, we solidified our market position through core brand strengths and strategic investments. Despite facing challenges in the external environment, we remain confident in the long-term opportunities for our transition to smokeless products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
British American Tobacco’s (BAT) nicotine pouch brand Velo has released a global consumer study and launched its “Echoes of Tomorrowland” campaign with electronic music festival brand Tomorrowland. The research surveyed 2,009 nicotine users across the UK, Spain, Pakistan, Poland and Austria. Velo said 61% of respondents feel more comfortable expressing themselves when they see others doing the same, while 39% said building meaningful connections becomes harder with age. The campaign reflects how nicotine pouch brands are increasingly using music, communities and lifestyle marketing to build consumer engagement.
Aug.10
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19